企业信息
17
  • 入驻时间: 2008-08-20
  • 联系人:客户经理
  • 电话:400-968-7988
  • 联系时,请说明易展网看到的
  • Email:fuwu@bioleaf.com
产品详情
  • 产品名称:Severe Fever with Thrombocytopenia Syndrome Virus Nucleoprotein

  • 产品型号:
  • 产品厂商:其它品牌
  • 产品价格:399
  • 折扣价格:0
  • 产品文档:
你添加了1件商品 查看购物车
简单介绍:

Recombinant Severe Fever with Thrombocytopenia Virus Nucleoprotein incorporating a N-terminal 6xHis-tag expressed in mammalian HEK293 mammalian cells, at 95% purity.

详情介绍:

Severe Fever with Thrombocytopenia Syndrome Virus Nucleoprotein

Severe fever with thrombocytopenia syndrome virus Nucleoprotein (SFTSV) is a segmented, negative-strand RNA Phlebovirus belonging to the Bunyaviridae family. SFTSV is a newly identified bunyavirus, which was first recognised in China in 2009 (Yu, XJ). Since 2009, reported cases of SFTSV infection have increased dramatically, occurring predominantly in China, South Korea and Japan, but also in the United states and Mediterranean countries.

SFTSV is a tick-borne virus that can be transmitted to humans by Haemaphysalis longicornis, a member of the Ixodidae family. H. longicornis, is endemic in the Asia-Pacific region and has a wide variety of hosts including livestock, birds, wild and domestic mammals. In some cases, animals infected with SFTSV do not exhibit clinical symptoms and are thought to act as intermediate reservoirs of the virus. Other ticks may act as vectors for SFTSV. However, bites from H. longicornis have been directly linked to cases of human SFTSV infection. Transmission of SFTSV from person-to-person has also been reported in some cases, due to contact with infected blood or mucus (Zhuang, L).

In humans the clinical symptoms associated with SFTSV infection include a high fever, abdominal pain, nausea, myalgia, a dramatic reduction of platelets and leukocytes, raised serum enzyme levels and, in some cases, multi-organ failure. Fatality rates due to SFTSV infection vary between 2- 30% and hospitalization may occur more frequently in the elderly and immunocompromised patients (WHO).

Currently, there is no licensed prophylactic vaccine or specific antiviral treatment for SFTSV infection. SFTSV is recognised by the World Health Organization as an emerging highly pathogenic virus, which presents a significant threat to human health.

At The Native Antigen Company we have developed recombinant SFSTV Nucleoprotein, expressed in mammalian HEK293 cells.  The protein comprises amino-acids 2-245, and incorporates an N-terminal His-tag linked via a 10 amino-acid glycine-serine linker.  The protein is approximately 30kD by SDS-PAGE analysis.

References

Yu, XJ et al. (2011). Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. Apr 21;364(16):1523-32

Zhuang L et al. (2018). Transmission of Severe Fever with Thrombocytopenia Syndrome Virus by Haemaphysalis longicornis Ticks, China. Emerg Infect Dis. May;24(5).

World Health Organization: Risk assessment of human infection with a novel bunyavirus in China.

 

 


Certificate of Analysis

Safety Datasheet

标题:
内容:
联系人:
联系电话:
Email:
公司名称:
联系地址:
 
 
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!
相关文章

沪公网安备 31011202007337号